Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-DLL3 antibody-drug conjugate FZ-AD005

An antibody-drug conjugate (ADC) composed of FZ-A038, a monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), conjugated, via a valine-alanine (Val-Ala) dipeptide linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration, anti-DLL3 ADC FZ-AD005 targets and binds to DLL3-expressing tumor cells. Upon binding and internalization, DXd is released. DXd inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of DLL3-expressing tumor cells. FZ-AD005 is also able to induce a bystander effect on neighboring cells in the tumor environment. This further inhibits the proliferation of tumor cells. In addition, FZ-AD005 is Fc-silenced, which may prevent Fc gamma receptor (FcgR)-mediated toxicities. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development, tumor initiation and proliferation.
Synonym:ADC FZ-AD005
anti-DLL3 ADC FZ-AD005
FZ-A038/DXd ADC FZ-AD005
Code name:FZ AD005
FZ-AD005
FZAD005
Search NCI's Drug Dictionary